EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study

Xia Yin, Qiang He, Dan Liu, Linna Xie, Hui Wang, Chunyan Chen, Chuanli Zhao, Ningning Shan, Shanshan Shi, Haichen Wei, Ji Ma, Ke Lu und 4 weitere

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35697 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 03.01.2025. Verfasst von Xia Yin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Sh…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Rituximab, Vincristine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shandong Excellent Youth Science Fund Project, Start-up Fund of Shandong Cancer Hospital, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Double‐expressor lymphoma (DEL) has a poorer prognosis than other subtypes of diffuse large B‐cell lymphoma (DLBCL). This study is a multicenter, prospective, single‐arm, phase 2 clinical study initiated by investigators to evaluate the efficacy and safety of combined zanubrutinib with R‐CHOP, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for patients with DEL (stage II or more), as well as to explore factors related to efficacy preliminarily.

Methods

From November 2020 to July 2022, 48 newly diagnosed patients were enrolled. All patients received twice‐daily oral zanubrutinib (160 mg) for 6 months and standardized R‐CHOP regimen for six to eight cycles.

Results

The objective response rate (ORR) was 89.6%, with a complete response rate (CRR) of 83.3%. The median follow‐up was 29.3 months. The median progression‐free survival (PFS) and overall survival (OS) were not reached. The PFS and OS were 81.25% and 93.75% at 2 years, respectively. Grade ≥3 adverse events (AEs) were reported in 23 of 48 (47.9%) patients. Next‐generation sequencing (NGS) results of 33 patients showed that TP53 , MYD88 , and PIM1 were the most common mutated gene. Multivariate analysis revealed that BCL‐6 gene rearrangement was an adverse prognostic factor for both PFS (hazard ratio [HR], 0.247; 95% confidence article [CI], 0.068–0.9; p = .034) and OS (HR, 0.057; 95% CI, 0.006–0.591; p = .016), whereas the number of extranodal involvements also significantly influenced OS (HR, 15.12; 95% CI, 1.07–213.65; p = .044).

Conclusions

Zanubrutinib in combination with R‐CHOP is an effective option for DEL patients, and the toxicity of zanubrutinib is entirely acceptable for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideRituximabVincristineDoxorubicinPrednisonePyrazolesLymphoma, Large B-Cell, DiffuseHumansFemaleMaleMiddle AgedAgedAdultProspective StudiesPyrimidinesProto-Oncogene Proteins c-bcl-6Myeloid Differentiation Factor 88Progression-Free SurvivalPiperidinesTumor Suppressor Protein p53

Stichwörter der Autor:innen

BCL2BTKiMYCdouble‐expressor lymphomazanubrutinib

Substanzen

CyclophosphamideRituximabVincristinezanubrutinibDoxorubicinPrednisonePyrazolesR-CHOP protocolPyrimidinesMYD88 protein, human

Autor:innen und Institutionen

  • Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
  • Department of Hematology, Jining First People's Hospital, Jining, Shandong, China.

ORCID-Profile: Zengjun Li

Förderung

  • Shandong Excellent Youth Science Fund Project
  • Start-up Fund of Shandong Cancer Hospital
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Yin, X., He, Q., Liu, D., Xie, L., Wang, H., Chen, C., Zhao, C., Shan, N., Shi, S., Wei, H., Ma, J., Lu, K., Wang, L., Wang, Y., Xing, L., & Li, Z. (2025). Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study. Cancer, 131(1). https://doi.org/10.1002/cncr.35697

Vancouver

Yin X, He Q, Liu D, Xie L, Wang H, Chen C, et al. Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study. Cancer. 2025;131(1). doi:10.1002/cncr.35697

BibTeX
@article{Yin2025,
  author = {Yin, Xia and He, Qiang and Liu, Dan and Xie, Linna and Wang, Hui and Chen, Chunyan and Zhao, Chuanli and Shan, Ningning and Shi, Shanshan and Wei, Haichen and Ma, Ji and Lu, Ke and Wang, Liang and Wang, Yan and Xing, Lijie and Li, Zengjun},
  title = {Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35697}
}
Kostenlos starten →